



Supplementary Fig. S19: CSF1R inhibition abrogates anti-glioma efficacy of B7H3 CAR T-cells. GL261 glioma-bearing mice were treated with BLZ945 at 200mg/Kg followed by CAR T-cell injection intratumorally. **(A)** Tumor volumes determined from MRI in mice treated with BLZ945 (drug) in combination with Ctrl or B7-H3 CAR T-cells. **(B)** Representative pictures from immunostaining of F4/80 and CD11c from mice treated with BLZ945 combination with B7H3 CAR T-cells at 40x magnification (scale bar = 100 μ m). **(C)** Summary plot of F4/80 and CD11c quantitative analysis as evaluated by blinded pathologist ($P < 0.001$). **(D)** Experimental scheme of BLZ945 treatment in combination with B7-H3 CAR T-cells starting with daily drug dosing 4-days prior to tumor implantation followed by CAR T-cell treatment at day-7 post implantation. **(E)** Kaplan-Meier survival curve. $N=5$. $P < 0.05$